MITF and melanoma: Opposing AXL/MITF expression in melanoma subsets has gained recent interest, because MITF-low/AXL-high expression signatures were found in tumors of a subgroup of melanoma patients resistant to BRAF/MEK inhibitor treatment [39,40].